LTRN · Lantern Pharma Inc.
$2.65
+0.14 (+5.58%)
At close · Jul 30
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the existence of substantial doubt regarding our ability to continue as a going concern in the absence of obtaining substantial additional funding”View the 10-Q filed May 15, 2026
Market Cap
$28.37M
Shares
11.30M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$17.12M
+17.6%
FY2025
Diluted EPS
-$1.57
+18.7%
FY2025
Operating Cash Flow
-$15.68M
+12%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $9.98M | $11.51M | $16.13M | $11.89M | $8.6M | $7.57M | $10K | |
| $6.63M | $6.46M | $6.09M | $5.98M | $5.83M | $5.02M | $3.66M | |
| — | $17.28K | $17.28K | $14.62K | $10.08K | $6761 | $3388 | |
| $16.61M | $17.98M | $22.22M | $17.88M | $14.43M | $12.59M | $5.91M | |
| -$16.61M | -$17.98M | -$22.22M | -$17.88M | -$14.43M | — | — | |
| $367.58K | $421.13K | $692.87K | $1.15M | -$31.55K | $160.55K | — | |
| -$15.91M | -$17.12M | -$20.78M | -$15.96M | -$14.26M | -$12.36M | -$5.91M | |
| — | — | — | — | — | $12.36M | — | |
| — | — | — | — | — | -$12.36M | — | |
| -$16.08M | -$17.25M | -$20.52M | -$15.7M | -$14.54M | — | — | |
| USD/shares | — | -$1.57 | -$1.93 | -$1.47 | -$1.31 | — | — |
| USD/shares | — | -$1.57 | -$1.93 | -$1.47 | — | — | — |
| shares | — | 10.9M | 10.76M | 10.84M | 10.85M | 10.9M | 4.3M |
| shares | — | 10.9M | 10.76M | 10.84M | — | 10.9M | 4.3M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2024: $3.48M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 11.86×
EV/EBIT
—
P/E (TTM)
—
Peer median 0.96×
Peer medians compare against the 264 similar-size Biotechnology companies (of 522 listed).